Femasys, Inc. (FEMY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Femasys, Inc. (FEMY)
Company Performance

Current Price

as of Oct 16, 2024

$1.23

P/E Ratio

N/A

Market Cap

$27.35M

Description

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Metrics

Overview

  • HQSuwanee, GA
  • SectorElectronic Technology
  • IndustryElectronic Equipment/Instruments
  • TickerFEMY
  • Price$1.23+5.13%

Trading Information

  • Market Cap$27.35M
  • Float92.38%
  • Average Daily Volume (1m)111,715
  • Average Daily Volume (3m)138,473
  • EPS-$0.84

Company

  • Revenue$0.95M
  • Rev Growth (1yr)-30.90%
  • Net Income-$4.68M
  • Gross Margin-29.70%
  • EBITDA Margin-1,927.01%
  • EBITDA-$4.27M
  • EV$18.86M
  • EV/Revenue19.85
  • P/EN/A
  • P/S28.76
  • P/B2.43
Documents
SEC Filings
8-K (2024-09-11)
8-K (2024-09-09)
8-K (2024-08-30)
8-K (2024-08-29)
8-K (2024-08-08)
8-K (2024-07-12)
8-K (2024-06-20)
8-K (2024-05-09)
8-K (2024-04-24)
8-K (2024-03-28)
8-K (2024-03-20)
8-K (2024-03-06)
8-K (2024-02-28)
8-K (2024-02-06)
8-K (2023-11-29)
8-K (2023-11-21)
8-K (2023-11-15)
8-K (2023-11-14)
8-K (2023-10-11)
8-K (2023-10-03)
8-K (2023-09-27)
8-K (2023-09-06)
8-K (2023-08-10)
8-K (2023-08-03)
8-K (2023-07-27)
8-K (2023-06-26)
8-K (2023-06-21)
8-K (2023-06-15)
8-K (2023-06-08)
8-K (2023-06-02)
8-K (2023-05-11)
8-K (2023-05-04)
8-K (2023-04-20)
8-K (2023-04-18)
8-K (2023-03-31)
8-K (2023-03-30)
8-K (2023-03-13)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-14)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-03-28)
10-K (2023-03-30)
Factset Street Account
Femasys, Inc. reports Q3 EPS ($0.26) vs FactSet ($0.22) [4 est, ($0.25)-(0.19)] ($1.04, 0.00) (2023-11-14T12:14:38Z)
Femasys, Inc. MDSAP surveillance audit successfully completed ($3.89, 0.00) (2023-10-03T12:33:46Z)
Femasys, Inc. files prospectus supplement to equity distribution agreement with Piper Sandler; to sell up to $16.7M of common stock - 8-K ($3.89, 0.00) (2023-10-03T13:34:15Z)
Femasys completes Stage 2 European Union (EU) Medical Device Regulation (MDR 2017/745) onsite audit resulting in zero nonconformances and no findings ($1.20, 0.00) (2023-10-26T12:33:56Z)
Femasys appoints James Liu as Chief Medical Officer, succeeding Edward Evantash ($0.98, 0.00) (2023-11-30T13:32:19Z)
Femasys announces completion of enrollment in pivotal trial of FemaSeed ($1.03, 0.00) (2023-11-28T13:33:04Z)
Femasys announces $6.85M convertible note investment from investors led by PharmaCyte Biotech (PMCB) ($0.93, 0.00) (2023-11-15T12:40:25Z)